Navigation Links
Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
Date:5/5/2010

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance. Furthermore, the results associated CD24 expression with the new (seventh) edition of the TNM staging. In summary, the study concluded that high expression of CD24 was a negative independent prognostic factor for progression free and cancer-specific survival in NSCLC.

The metastasis-associated protein CD24 found within a tumor has been identified as a new prognostic factor and stem cell marker; however, the importance of the CD24 in NSCLCs has not been made clear through previously existing research. To clarify the understanding, the present study conducted a retrospective study of prognostic factor analysis by evaluating CD24 expression in 267 consecutive cases of NSCLC. Using a tissue microarray technique the team analyzed the immunohistochemistry that correlated with clinicopathologic parameters.

The specific study findings revealed that CD24-high expression was demonstrated in 33 percent of the NSCLC cases, specifically 87 of 267. Expression rate also associated more so with adenocarcinoma histology (39 percent) than in squamous cell carcinoma histology (23 percent). Patients with CD24-high tumors also tended to have a higher risk of disease progression and cancer-related death. Furthermore, CD24-high expression aligned with new pathologic stages rather than old p-stages.

Prior to the revision of the TNM staging, the most important conventional prognostic factor for patient survival was tumor stage at the time of diagnosis, including tumor size, pleura invasion, involvement of regional lymph nodes and metastatic spread to distant organs. However, the revised guidelines found age, gender and performance status (PS), in addition to stage, all to be prognostic factors for survival. Within the current study, expression correlated with PS and new p-stage; furthermore, age correlated with progression free survival and cancer-specific survival, regardless of tumor histology.

"Biomarkers that are over-expressed during cancer progression are of special interest because they may not only be used to predict patient outcome but also serve as potential targets in cancer therapy like epidermal growth factor receptor (EGFR) gene," lead investigator Dr. Hyun Ju Lee relays the implications of the research findings.


'/>"/>

Contact: Megan Richter
mrichter@spectrumscience.com
202-587-2556
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. New research identifies modifiable risk factors for heart disease
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Researcher to track spread of disease, malware and power outages
4. UCSF Researchers Identify Regulator of Human Sperm Cells
5. Octapharma Accepting Applications for Research Grants Through March 31
6. Valentine Tailgate Party for the Girls with Festive Ideas from Beauty Research
7. New Research Shows Genes of Pregnant Women and Their Fetuses Can Increase the Risk of Preterm Labor
8. University of Maryland chemist receives Astellas Award for blindness prevention research
9. Developing a cyberinfrastructure for comparative effectiveness in cancer research
10. Women should be allowed to eat, drink during labor: Queens University researcher
11. Parkinsons disease research uncovers social barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: